CD274 and non-small cell lung carcinoma: As for pembrolizumab monotherapy specifically, a number of studies have suggested its lack of cost-effectiveness in treating patients with metastatic NSCLC in China (42), the United States (43), the United Kingdom (44), and Singapore (45), although some contradictory results supported its cost-effectiveness in some scenarios, such as in patients with PD-L1 expression ≥50% (43), compared with docetaxel (46), or higher threshold of WTP (47).